UBI Ubisoft Entertainment SA

Ubisoft Announces its Global Creative Office

Ubisoft Announces its Global Creative Office

  
 
Ubisoft Announces its Global Creative Office



The new organization aims to further grow the value of Ubisoft’s brands by boosting game creation, delivery and fostering the autonomy of creative teams in studios
 



 







 
PARIS – October 6, 2022 – Today, Ubisoft is announcing the implementation of its Global Creative Office to better reflect and support its portfolio strategy. With this evolution, Ubisoft aims to further support creative teams by facilitating decision-making and strengthening the responsibility and autonomy of studios throughout the creative process. The overall goal is to boost creativity and ensure the highest level of quality in the execution and delivery of Ubisoft's games.



 



The new Creative Office will be structured around poles, moving away from a centralized organization to better support the key segments of Ubisoft’s portfolio strategy. Building on the Group’s vision, each pole will leverage its expertise to dive into the specificities of its audiences, game design and tech.



 



Chief Creative Officer Igor Manceau, who was instrumental in refining the group’s creative vision and in laying the foundations of this new organization, will leave Ubisoft for personal reasons at the end of November. In the meantime, Igor will continue refining the structure, in close collaboration with Marie-Sophie de Waubert, SVP of Studios, Martin Schelling, SVP of Production, Sandrine Caloiaro, Chief Portfolio Officer, Guillemette Picard, SVP of Production Technology and studio Managing Directors. Following Igor’s departure, Marie-Sophie will temporarily take over management of the Creative Office to ensure a smooth transition across teams and projects.



 



“In a fast-moving industry, it’s essential that we continue to adapt. I am grateful for Igor’s contribution to refining Ubisoft’s creative approach and for his commitment to bringing fresh ideas that level up the way we create,” said Yves Guillemot, CEO and Co-Founder, Ubisoft. “An exemplary leader, Igor has set the foundations for a new organization that will allow Ubisoft to successfully deliver on its content strategy, with new processes and clearer roles and responsibilities.”



 



"Over the last 24 years I got the chance to meet and work with talented and inspiring teams around the world. I am grateful for the opportunity to have taken part in this fantastic adventure.” Said Manceau. “I am confident in Ubisoft’s potential to continue surprising and delighting players for years to come”.

  

# # #

Contacts

Investor Relations

Jean-Benoît Roquette

SVP Investor Relations

39

Press Relations

Fabien Darrigues

Director of Global Communications

   

Alexandre Enjalbert

Senior Investor Relations Manager

78

About Ubisoft

Ubisoft is a creator of worlds, committed to enriching players’ lives with original and memorable entertainment experiences. Ubisoft’s global teams create and develop a deep and diverse portfolio of games, featuring brands such as Assassin’s Creed®, Brawlhalla®, For Honor®, Far Cry®, Tom Clancy’s Ghost Recon®, Just Dance®, Rabbids®, Tom Clancy’s Rainbow Six®, The Crew®, Tom Clancy’s The Division®, and Watch Dogs®. Through Ubisoft Connect, players can enjoy an ecosystem of services to enhance their gaming experience, get rewards and connect with friends across platforms. With Ubisoft+, the subscription service, they can access a growing catalog of more than 100 Ubisoft games and DLC. For the 2021–22 fiscal year, Ubisoft generated net bookings of €2,129 million. To learn more, please visit:

© 2022 Ubisoft Entertainment. All Rights Reserved. Ubisoft and the Ubisoft logo are registered trademarks in the US and/or other countries.

 

Attachment



EN
06/10/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ubisoft Entertainment SA

 PRESS RELEASE

Informations sur les droits de vote et les actions au 30 septembre 202...

Informations sur les droits de vote et les actions au 30 septembre 2025 Le 8 octobre 2025 Information relative au nombre total de droits de vote et d’actions composant le capital social   Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers Place de cotation :        Euronext ParisCompartiment :        Compartiment ACode ISIN :                FR0000054470Site web :                 Information mensuelle au 30 septembre 2025(Articles L. 233-8, II, du Code de commerce et 223-16 du Règlement Général de l’Autorité des Marchés Financiers) Date Nombre total ...

Wedbush Research
  • Wedbush Research
UBI UBISOFT ENTERTAINMENT SA
XNCR XENCOR INC.
XENE XENON PHARMACEUTICALS INC
WDC WESTERN DIGITAL CORPORATION
VYGR VOYAGER THERAPEUTICS INC.
TTWO TAKE-TWO INTERACTIVE SOFTWARE INC.
TSLA TESLA INC
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
RARE ULTRAGENYX PHARMACEUTICAL INC.
PEGA PEGASYSTEMS INC.
PANW PALO ALTO NETWORKS INC.
NVCR NOVOCURE LTD.
NBIX NEUROCRINE BIOSCIENCES INC.
KURA KURA ONCOLOGY INC.
IMAX IMAX CORPORATION
GERN GERON CORP.
FATE FATE THERAPEUTICS INC
CTMX CYTOMX THERAPEUTICS INC.
CHKP CHECK POINT SOFTWARE TECHNOLOGIES LTD.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ARDX ARDELYX INC
CDR CD PROJEKT S.A.
FRX_CN FENNEC PHARMACEUTICALS
7974 NINTENDO CO. LTD.
EA ELECTRONIC ARTS INC.
ANAB ANAPTYSBIO INC.
ARGX ARGENX ADS
MRSN MERSANA THERAPEUTICS
ISR ISORAY
AMZN AMAZON.COM INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
IBM INTERNATIONAL BUSINESS MACHINES CORPORATION
APLS APELLIS PHARMACEUTICALS
ZG ZILLOW GROUP INC. CLASS A
DNLI DENALI THERAPEUTICS INC
RCUS ARCUS BIOSCIENCES
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
REPL REPLIMUNE GROUP
ARVN ARVINAS HOLDING
STRO SUTRO BIOPHARMA
CRWD CROWDSTRIKE HOLDINGS INC. CLASS A
STOK STOKE THERAPEUTICS
IDYA IDEAYA BIOSCIENCES
PASG PASSAGE BIO
BDTX BLACK DIAMOND THERAPEUTICS
ACET ADICET BIO INC
KROS KEROS THERAPEUTICS
ZNTL ZENTALIS PHARMACEUTICALS
BEAM BEAM THERAPEUTICS
LRMR LARIMAR THERAPEUTICS INC
PRAX PRAXIS PRECISION MEDICINES
U UNITY SOFTWARE
TVTX TRAVERE THERAPEUTICS INC
VRDN VIRIDIAN THERAPEUTICS INC
PLTK PLAYTIKA HOLDING
RBLX ROBLOX
DAWN DAY ONE BIOPHARMACEUTICALS INC
APP APPLOVIN CORP
ATXS ASTRIA THERAPEUTICS INC
GMTX GEMINI THERAPEUTICS INC
TYRA TYRA BIOSCIENCES INC
EWTX EDGEWISE THERAPEUTICS INC
APGE APOGEE THERAPEUTICS INC
EMBRAC B EMBRACER GROUP AB
DNTH DIANTHUS THERAPEUTICS INC
LAC. LITHIUM AMERICAS CORP NEW
ORKA ORUKA THERAPEUTICS INC
ZBIO ZENAS BIOPHARMA INC.
TLX TELIX PHARMACEUTICALS LIMITED
MAZE MAZE THERAPEUTICS INC
 PRESS RELEASE

Informations sur les droits de vote et les actions au 31 août 2025

Informations sur les droits de vote et les actions au 31 août 2025    Le 11 septembre 2025 Information relative au nombre total de droits de vote et d’actions composant le capital social   Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers Place de cotation :        Euronext ParisCompartiment :        Compartiment ACode ISIN :                FR0000054470Site web :                 Information mensuelle au 31 août 2025(Articles L. 233-8, II, du Code de commerce et 223-16 du Règlement Général de l’Autorité des Marchés Financiers) Date Nombre total d’actions composa...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch